Carcinoembryonic Antigen Global Market Predicted to Augment and Reach over $2.02 Billion at a CAGR of 13.5% By 2028
Global carcinoembryonic antigen market size is expected to reach $2.02 Bn by 2028 at a rate of 13.5%, segmented as by test type, molecular tests, serology tests
Share this Post to earn Money ( Upto ₹100 per 1000 Views )
The carcinoembryonic antigen from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Carcinoembryonic Antigen Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size -
The carcinoembryonic antigen market size has grown rapidly in recent years. It will grow from $1.07 billion in 2023 to $1.22 billion in 2024 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to cancer prevalence globally, aging population, awareness campaigns, healthcare infrastructure development, and reimbursement policies.
The carcinoembryonic antigen market size is expected to see rapid growth in the next few years. It will grow to $2.02 billion in 2028 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to focus on early detection and prevention, expansion of cancer screening programs, patient demand for personalized medicine, growing demand for minimally invasive diagnostic procedures. Major trends in the forecast period include increased adoption of personalized medicine, technological advancements in diagnostic platforms, integration with artificial intelligence and big data, collaborations and partnerships, and regulatory approvals and reimbursement policies.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/carcinoembryonic-antigen-global-market-report
Scope Of Carcinoembryonic Antigen Market
The Business Research Company's reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Carcinoembryonic Antigen Market Overview
Market Drivers -
The increase in cancer incidence is expected to propel the growth of the carcinoembryonic antigen market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells. There is a growing incidence of cancer due to factors such as lifestyle choices, environmental pollution, genetic predisposition, and an aging population. Carcinoembryonic antigen (CEA) is a tumor marker used in cancer to monitor disease progression and treatment effectiveness. For instance, in February 2024, according to the World Health Organization (WHO), a US-based intergovernmental organization, approximately 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the rise in cancer incidence is driving the growth of the carcinoembryonic antigen market.
Market Trends -
Major companies operating in the carcinoembryonic antigen market are increasing their focus on developing tumor marker tests to advance the testing process and enhance diagnostic offerings. Tumor marker tests are diagnostic procedures used to detect the presence of specific substances in the body that may indicate the presence of cancer. For instance, in October 2021, Boditech Med, a South Korea-based company that develops and manufactures products for in-vitro diagnostics and diagnostic reagents, launched the ichroma Tumor triple-M diagnostic kit. It is a tumor marker tests kit approved by the Ministry of Food and Drug Safety, capable of measuring three tumor markers prostate-specific antigen (PSA), alpha-fetoprotein (AFP), and carcinoembryonic antigen (CEA) simultaneously. The kit aids in early diagnosis of common cancers like prostate, liver, and colon cancer. The product's ability to provide rapid results within 15 minutes using whole blood offers cost and time-saving advantages.
The carcinoembryonic antigen market covered in this report is segmented –
1) By Test Type: Molecular Tests, Serology Tests
2) By Gender: Male, Female
3) By Application: Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Lung Cancer, Thyroid Cancer, Ovarian Cancer, Other Applications
4) By End User: Hospitals, Diagnostic Centers, Cancer Centers, Research And Academic Institutes
Get an inside scoop of the carcinoembryonic antigen market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=16011&type=smp
Regional Insights -
North America was the largest region in the carcinoembryonic antigen market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoembryonic antigen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies -
Major companies operating in the carcinoembryonic antigen market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthineers, Laboratory Corporation of America Holdings, Quest Diagnostics, Agilient Technologies, Inc., Beckman Coulter Inc., bioMérieux SA, Quidel Corporation, Ortho Clinical Diagnostics, Abcam plc, RayBiotech Inc., Creative Diagnostics, Lee Biosolutions Inc., Hytest Ltd., Prospec-Tany Technogene Ltd, Boster Biological Technology, Metropolis Healthcare
Table of Contents
1. Executive Summary
2. Carcinoembryonic Antigen Market Characteristics
3. Carcinoembryonic Antigen Product
4. Carcinoembryonic Antigen Market Trends And Strategies
5. Carcinoembryonic Antigen Market - Macro Economic Scenario
.....
31. Carcinoembryonic Antigen Market Other Major And Innovative Companies
32. Global Carcinoembryonic Antigen Market Competitive Benchmarking
33. Global Carcinoembryonic Antigen Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Carcinoembryonic Antigen Market
35. Carcinoembryonic Antigen Market Future Outlook and Potential Analysis
36. Appendix
Explore the trending research reports from TBRC:
https://topprnews.com/gluten-feed-market
https://topprnews.com/organic-feed-market
https://topprnews.com/organic-pigments-market
https://goodprnews.com/rapeseed-oil-market
https://goodprnews.com/gluten-feed-market
https://goodprnews.com/manufactured-soil-market
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info
Healthcare Blog: https://healthcareresearchreports.com
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model